03:05 PM EDT, 03/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Following the recent sell-off in TXG shares after the Q4 earnings release in February, we think shares are attractive at current levels. We lower our target by $9 to $43 based on our DCF analysis. We narrow our 2024 loss per share (LPS) estimate to $1.35 from $1.39 and keep 2025's LPS view at $0.61. We recently upgraded our outlook on the Life Sciences Tools and Services sub-industry to Neutral from Negative as we anticipate a gradual recovery starting in the second half of 2024. In a year where we already expect TXG to grow revenues by 10% Y/Y, we think the company can further benefit from these global recovery trends. At the same time, we look favorably upon the recent key product launches. On March 13, TXG announced the shipment of its first Chromium GEM-X products, which is the next generation of TXG's single cell technology, aiming to execute faster and at lower costs. Today, TXG launched its Visium HD spatial gene expression product, which is expected to be a game changer in spatial discovery research.